Floatz logo

FILGRASTIM

B-cell Lymphoma

Ahmed Galal, MDprotein_peptidePhase 2Dormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
66/ 100
Competitive Position
73/ 100

Competitive context

46 Active assets in the B-cell Lymphoma cohort.

Asset / SponsorPhaseRating
Glofitamab
Brown University
Phase 4BB
Pirtobrutinib
Nurix Therapeutics, Inc.
Phase 3BB
Evomela
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 4BB
Obinutuzumab
Brown University
Phase 2BB
Fludarabine
Swiss Cancer Institute
Phase 2BB

View all 50 →

Same molecule, other indications

FILGRASTIM is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
79 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →